Washington, New York-based Aceto said the latest deal, its fourth in 2021, complements last April’s purchase of A&C – to which A&C Bio Buffer previously belonged – and reinforces its efforts toward developing its business with the biopharmaceutical sector.

In addition to biological buffers, the acquired company’s portfolio includes process solutions, cleaning solutions and WFI (water for injection) made at its plant in Limerick, Ireland.

Aceto said it will continue to support A&C BioBuffer’s manufacturing facilities and offices in Ireland. In the words of CEO Gilles Cottier, it is “a natural add-on to our acquisition of A&C and aligns with our commitments to the biopharmaceutical space.” He noted that the company’s reputation for service and quality recently led to its key role in the raw material supply chain for Covid-19 vaccines.

The buy also enhances Aceto’s growing European manufacturing footprint and commercial presence, Cotter said. “We believe the shared lineage reflected in A&C Bio Buffer’s skills, culture and customer focus will further support our evolution as a leading supplier of critical raw materials in the life sciences sector.”

After several buyouts in 2020, the New York-based firm’s appetite for acquisitions remains undiminished. Immediately following last spring’s takeover of A&C, it bought a majority stake in Finar, an Indian manufacturer, supplier and distributor of pharmaceutical excipients as well as lab chemicals, aquaculture inputs and food grade additives. In June, it acquired Eugene, Oregon-based Cascade Chemistry, a US manufacturer of active pharmaceutical ingredients (APIs), regulatory starting materials and advanced intermediates.

Author: Dede Williams, Freelance Journalist